Navigation Links
The Asthma Drug Market Will Remain Relatively Flat, Increasing Slightly from $15.3 Billion in 2012 to $16.2 Billion in 2022
Date:12/18/2013

BURLINGTON, Mass., Dec. 18, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the drug market for asthma will remain relatively flat through 2022. Currently, the market is driven by maintenance therapies that successfully treat patients with mild and moderate disease, including market leaders GlaxoSmithKline's long-acting beta2 agonist (LABA)/inhaled corticosteroid (ICS) combination Advair/Seretide/Adoair and Merck's leukotriene inhibitor Singulair (montelukast). These leading agents are already beginning to face generic erosion that will lead their sales to decline.

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36784LOGO)

The Pharmacor advisory service entitled Asthma finds that the overall market for asthma will remain stable, increasingly slightly from $15.3 billion in 2012 to $16.2 billion in 2022 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan. However, the makeup of the biggest sellers in the market will differ in 2022. As the current market leaders undergo generic erosion, including a substantial 67 percent drop in montelukast's sales over the forecast period, asthma sales in later years will be driven by the uptake of GlaxoSmithKline/Theravance's once-daily LABA/ICS combination Breo/Relvar and by four novel anticytokine agents that will serve part of the unmet need in the severe, refractory asthma population.

"Physicians are waiting for more options for their severe, refractory patients beyond oral corticosteroids and the lone biologic approved for asthma, Genentech/Novartis's Xolair, so they are eager to use the new biologics in specific patients," said Decision Resources Analyst Colleen E. Albacker, Ph.D. "Although we anticipate low patient share for these emerging agents, their high price tags will help to offset declining sales due to generic entry of the current market leaders."

The report also finds that Breo/Relvar will perform strongly and act as another key growth driver in the asthma market. Breo/Relvar's once-daily administration will be the first to offer dosing improvement over currently-marketed twice-daily LABA/ICS combinations, and an aggressive marketing campaign will enable it to begin to challenge Advair's dominance in all major markets, although Advair will remain the asthma sales leader.

About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.


'/>"/>
SOURCE Decision Resources
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. ViroPharma Announces Upcoming Data Presentations at the 2013 American College of Allergy, Asthma and Immunology (ACAAI) Annual Scientific Meeting
2. Cytos Biotechnology Ltd Announces the Completion of Patient Enrolment in the On-going Phase 2b Study of CYT003 for the Treatment of Allergic Asthma
3. Data for Investigational Tiotropium Show Improved Lung Function and Sustained Bronchodilation in Patients with Moderate Asthma Severity
4. Bronchiale Thermoplastie bietet anhaltende reduktion schwerer Asthmaanfälle über 5 jahre:
5. Bronchiale Tthermoplastie bietet anhaltende reduktion schwerer Asthmaanfälle über 5 jahre:
6. Rigels R343 Did Not Meet Primary Endpoint in Asthma Study
7. iSonea Receives Frost & Sullivan New Product Innovation Leadership Award for its Path-Breaking Mobile Asthma Monitoring App, AsthmaSense
8. Sharp Rees-Stealy Medical Centers Launches Asthmapolis Mobile Asthma Management Program
9. ARRY-502 Meets Primary And Key Secondary Endpoints In Asthma Study
10. Array Biopharma To Report Top-line Results From ARRY-502 Asthma Trial
11. Inspiro Medical Ltd. Completes a Successful First Clinical Trial in Asthmatic Children
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... PARSIPPANY, N.J. , Dec. 5, 2016 ... today announced preliminary safety and efficacy data from ... oral selective MDM2 inhibitor, suggesting that DS-3032 may ... relapsed/refractory acute myeloid leukemia (AML) and high-risk myelodysplastic ... part of the phase 1 study of DS-3032 were ...
(Date:12/5/2016)... , Dec. 5, 2016 Eisai Inc. announced ... the 2016 Annual Meeting of the American Epilepsy Society ... is indicated as an adjunctive therapy for the treatment ... generalized seizures and primary generalized tonic-clonic seizures (PGTC) in ... and older. Please see Important Safety Information for FYCOMPA, ...
(Date:12/5/2016)... BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage ... candidates, presents positive Phase 2a correlative data, as well as ... at the ongoing 58th American Society of Hematology (ASH) Annual ... . ... As previously announced, in ...
Breaking Medicine Technology:
(Date:12/5/2016)... ... ... Will Never Be The Same” is a fictional tale about growing up with the ... the creation of published author, Kim T. Briggs, a self-described “big kid” who has ... and philosophy from Judson University in Elgin, Illinois. Having written numerous Christian drama skits ...
(Date:12/5/2016)... (PRWEB) , ... December 05, 2016 , ... ... ability of physical therapist assistants, under direct supervision of a licensed physical therapist, ... physical therapy receives a consultation and treatment plan from a licensed physical therapist ...
(Date:12/5/2016)... IL (PRWEB) , ... December 05, 2016 , ... The ... to the individual looking to buy neoprene knee sleeves for lifting and ... The design focuses heavily on two main aspects to provide a higher quality knee ...
(Date:12/5/2016)... ... December 05, 2016 , ... ... an excellent way to ensure moisture measurements are consistently correct. However, regular ... , Now, METTLER TOLEDO offers a solution: SmartCal™ . This ...
(Date:12/5/2016)... ... December 05, 2016 , ... ... they have teamed up with The American College of Surgeons (ACS) to provide ... on Trauma, the “Bleeding Control Basic” course is a pilot program that fulfills ...
Breaking Medicine News(10 mins):